NCT06665997

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 65 (estimated)
• Sponsor: University of Pennsylvania · Academic / Other
• Sex: Female
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease. Participants in this study will be adult women with sickle cell disease who regularly experience sickle cell pain. They will complete a 3-month "baseline "with no use of hormonal contraception, and then a 3-month follow-up after receiving an injection of Depo-Provera. Participants will complete 6 to 7 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as complete remote weekly surveys and monthly home pregnancy tests.

Conditions

• Sickle Cell Disease (SCD)
• Vaso-Occlusive Pain Episode in Sickle Cell Disease

Interventions

Type	Name	Description
DRUG	Depot medroxyprogesterone acetate (DMPA)	150mg dose intramuscular administration of depot medroxyprogesterone acetate (DMPA) injectable suspension

Timeline

• Start date: 2025-06-26
• Primary completion: 2027-10-01
• Completion: 2027-10-01
• First posted: 2024-10-30
• Last updated: 2026-02-27

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study